Research programme: neurodegenerative disease protein therapeutics - Eleven Biotherapeutics

Drug Profile

Research programme: neurodegenerative disease protein therapeutics - Eleven Biotherapeutics

Latest Information Update: 21 Mar 2014

Price : $50

At a glance

  • Originator Eleven Biotherapeutics
  • Class Proteins
  • Mechanism of Action Cytokine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Peripheral nervous system diseases; Retinal disorders

Most Recent Events

  • 21 Mar 2014 No development reported for Peripheral nervous system diseases in USA (unspecified route)
  • 21 Mar 2014 No development reported for Retinal disorders in USA (unspecified route)
  • 12 Dec 2012 Early research in Peripheral nervous system diseases in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top